Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 229

1.

Autoimmunity in Alzheimer's disease as evidenced by plasma immunoreactivity against RAGE and Abeta42: complication of diabetes.

Mruthinti S, Schade RF, Harrell DU, Gulati NK, Swamy-Mruthinti S, Lee GP, Buccafusco JJ.

Curr Alzheimer Res. 2006 Jul;3(3):229-35.

PMID:
16842100
2.

Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides.

Mruthinti S, Buccafusco JJ, Hill WD, Waller JL, Jackson TW, Zamrini EY, Schade RF.

Neurobiol Aging. 2004 Sep;25(8):1023-32.

PMID:
15212827
3.
4.

Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls.

Xu W, Kawarabayashi T, Matsubara E, Deguchi K, Murakami T, Harigaya Y, Ikeda M, Amari M, Kuwano R, Abe K, Shoji M.

Brain Res. 2008 Jul 11;1219:169-79. doi: 10.1016/j.brainres.2008.02.060. Epub 2008 Mar 4.

PMID:
18534566
5.

Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease.

Sasaki N, Toki S, Chowei H, Saito T, Nakano N, Hayashi Y, Takeuchi M, Makita Z.

Brain Res. 2001 Jan 12;888(2):256-262.

PMID:
11150482
6.

RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease.

Donahue JE, Flaherty SL, Johanson CE, Duncan JA 3rd, Silverberg GD, Miller MC, Tavares R, Yang W, Wu Q, Sabo E, Hovanesian V, Stopa EG.

Acta Neuropathol. 2006 Oct;112(4):405-15. Epub 2006 Jul 25.

PMID:
16865397
7.

Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus.

Valente T, Gella A, Fernàndez-Busquets X, Unzeta M, Durany N.

Neurobiol Dis. 2010 Jan;37(1):67-76. doi: 10.1016/j.nbd.2009.09.008. Epub 2009 Sep 22.

PMID:
19778613
9.

Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease.

Lue LF, Yan SD, Stern DM, Walker DG.

Curr Drug Targets CNS Neurol Disord. 2005 Jun;4(3):249-66. Review.

PMID:
15975028
10.

Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine.

Blasko I, Jellinger K, Kemmler G, Krampla W, Jungwirth S, Wichart I, Tragl KH, Fischer P.

Neurobiol Aging. 2008 Jan;29(1):1-11. Epub 2006 Oct 19.

PMID:
17055615
11.
12.

The induction of surface beta-amyloid binding proteins and enhanced cytotoxicity in cultured PC-12 and IMR-32 cells by advanced glycation end products.

Mruthinti S, Sood A, Humphrey CL, Swamy-Mruthinti S, Buccafusco JJ.

Neuroscience. 2006 Oct 13;142(2):463-73. Epub 2006 Aug 4.

PMID:
16890367
13.

Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.

Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG.

Arch Neurol. 2007 Mar;64(3):354-62. Erratum in: Arch Neurol. 2007 Sep;64(9):1246.

PMID:
17353377
14.

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization.

Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C.

Neurology. 2003 Jul 8;61(1):46-54.

PMID:
12847155
15.

Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.

Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, Blennow K.

Dement Geriatr Cogn Disord. 2007;23(5):316-20. Epub 2007 Mar 19.

PMID:
17374949
16.

Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction.

Origlia N, Righi M, Capsoni S, Cattaneo A, Fang F, Stern DM, Chen JX, Schmidt AM, Arancio O, Yan SD, Domenici L.

J Neurosci. 2008 Mar 26;28(13):3521-30. doi: 10.1523/JNEUROSCI.0204-08.2008.

17.

Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals.

Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P.

Exp Gerontol. 2002 Jul;37(7):943-8.

PMID:
12086704
19.

Immune response to Abeta-peptides in peripheral blood from patients with Alzheimer's disease and control subjects.

Baril L, Nicolas L, Croisile B, Crozier P, Hessler C, Sassolas A, McCormick JB, Trannoy E.

Neurosci Lett. 2004 Jan 30;355(3):226-30.

PMID:
14732472
20.

Autoantibodies to amyloid-beta and Alzheimer's disease.

Hyman BT, Smith C, Buldyrev I, Whelan C, Brown H, Tang MX, Mayeux R.

Ann Neurol. 2001 Jun;49(6):808-10.

PMID:
11409436

Supplemental Content

Support Center